首页> 外文期刊>European Journal of Pharmacology: An International Journal >Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder.
【24h】

Successful methylphenidate treatment of early onset extreme obesity in a child with a melanocortin-4 receptor gene mutation and attention deficit/hyperactivity disorder.

机译:成功的哌醋甲酯治疗患有黑皮质素4受体基因突变和注意缺陷/多动障碍的儿童的早期发作的极端肥胖。

获取原文
获取原文并翻译 | 示例
       

摘要

We present the case report of a 2 year old boy with early onset extreme obesity (body mass index (BMI) 34.2 kg/m(2); body mass index standard deviation score (BMI-SDS) 5.4) who is heterozygous for a non-conservative functionally relevant melanocortin MC(4)receptor mutation (Glu308Lys) and who also showed severe symptoms of attention deficit/hyperactivity disorder (ADHD). Treatment with the stimulant methylphenidate led to a sharp decrease of BMI to 21.8 kg/m(2) (BMI-SDS 2.8) within 24 months. We discuss potential mechanisms for this unusually large weight loss and suggest a potential link between the melanocortinergic and the dopaminergic systems, and the sympathetic nervous system. The potential benefit of methylphenidate in obese melanocortin MC(4)receptor mutation carriers with and without co-morbid ADHD warrants further studies.
机译:我们提供了一个2岁男孩的案例报告,该男孩患有早期发作的极端肥胖(体重指数(BMI)34.2 kg / m(2);体重指数标准差评分(BMI-SDS)5.4),该男孩为非杂合性-保守功能相关的黑皮质素MC(4)受体突变(Glu308Lys),并且还表现出注意缺陷/多动症(ADHD)的严重症状。用兴奋性哌醋甲酯治疗导致BMI在24个月内急剧下降至21.8 kg / m(2)(BMI-SDS 2.8)。我们讨论了这种异常大的体重减轻的潜在机制,并提出了黑皮质素能和多巴胺能系统以及交感神经系统之间的潜在联系。哌醋甲酯在肥胖黑素皮质素MC(4)受体突变携带者中是否存在合并症ADHD的潜在益处值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号